These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 25805069)

  • 1. In vitro activity of fosfomycin in combination with colistin against clinical isolates of carbapenem-resistant Pseudomas aeruginosa.
    Di X; Wang R; Liu B; Zhang X; Ni W; Wang J; Liang B; Cai Y; Liu Y
    J Antibiot (Tokyo); 2015 Sep; 68(9):551-5. PubMed ID: 25805069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases.
    Santimaleeworagun W; Wongpoowarak P; Chayakul P; Pattharachayakul S; Tansakul P; Garey KW
    Southeast Asian J Trop Med Public Health; 2011 Jul; 42(4):890-900. PubMed ID: 22299471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic effects of fosfomycin and carbapenems against carbapenem-resistant Pseudomonas aeruginosa clinical isolates.
    Kunakonvichaya B; Thirapanmethee K; Khuntayaporn P; Montakantikul P; Chomnawang MT
    Int J Antimicrob Agents; 2015 May; 45(5):556-7. PubMed ID: 25724628
    [No Abstract]   [Full Text] [Related]  

  • 4. Phenotypic characterization and colistin susceptibilities of carbapenem-resistant of Pseudomonas aeruginosa and Acinetobacter spp.
    Mohanty S; Maurya V; Gaind R; Deb M
    J Infect Dev Ctries; 2013 Nov; 7(11):880-7. PubMed ID: 24240048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in vitro dynamic biofilm model.
    Lora-Tamayo J; Murillo O; Bergen PJ; Nation RL; Poudyal A; Luo X; Yu HY; Ariza J; Li J
    J Antimicrob Chemother; 2014 Sep; 69(9):2434-42. PubMed ID: 24833752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
    Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
    Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carbapenem-resistant Pseudomonas aeruginosa pneumonia with intermediate minimum inhibitory concentrations to doripenem: combination therapy with high-dose, 4-h infusion of doripenem plus fosfomycin versus intravenous colistin plus fosfomycin.
    Apisarnthanarak A; Mundy LM
    Int J Antimicrob Agents; 2012 Mar; 39(3):271-2. PubMed ID: 22236455
    [No Abstract]   [Full Text] [Related]  

  • 8. [Evaluation of In vitro Efficacy of Meropenem/Colistin and Meropenem/Fosfomycin Combinations on Multidrug Resistant Gram-Negative Bacilli].
    Adaleti R; Nakipoğlu Y; Arıcı N; Kansak N; Çalık Ş; Şenbayrak S; Balık R; Aksaray S
    Mikrobiyol Bul; 2023 Jul; 57(3):365-377. PubMed ID: 37462301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against Pseudomonas aeruginosa Producing Metallo-β-Lactamase.
    Albiero J; Mazucheli J; Barros JPDR; Szczerepa MMDA; Nishiyama SAB; Carrara-Marroni FE; Sy S; Fidler M; Sy SKB; Tognim MCB
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic (PK/PD) simulation.
    Asuphon O; Montakantikul P; Houngsaitong J; Kiratisin P; Sonthisombat P
    Int J Infect Dis; 2016 Sep; 50():23-9. PubMed ID: 27418581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro pharmacodynamics of fosfomycin against clinical isolates of Pseudomonas aeruginosa.
    Walsh CC; McIntosh MP; Peleg AY; Kirkpatrick CM; Bergen PJ
    J Antimicrob Chemother; 2015 Nov; 70(11):3042-50. PubMed ID: 26209311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In vitro activity of fosfomycin, alone or in combination, against clinical isolates of carbapenem resistant Pseudomonas aeruginosa].
    Gómez-Garcés JL; Gil-Romero Y; Sanz-Rodríguez N; Muñoz-Paraíso C; Regodón-Domínguez M
    Enferm Infecc Microbiol Clin; 2016 Apr; 34(4):228-31. PubMed ID: 26277206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of in vitro synergistic antibiotic interaction between fosfomycin and nonsusceptible antimicrobials in carbapenem-resistant Pseudomonas aeruginosa.
    Avery LM; Sutherland CA; Nicolau DP
    J Med Microbiol; 2019 Jun; 68(6):893-897. PubMed ID: 31050629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.
    Rodríguez-Avial I; Pena I; Picazo JJ; Rodríguez-Avial C; Culebras E
    Int J Antimicrob Agents; 2015 Dec; 46(6):616-21. PubMed ID: 26391381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination of colistin and fosfomycin is synergistic against NDM-1-producing Enterobacteriaceae in in vitro pharmacokinetic/pharmacodynamic model experiments.
    Albur MS; Noel A; Bowker K; MacGowan A
    Int J Antimicrob Agents; 2015 Nov; 46(5):560-7. PubMed ID: 26387065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of colistin alone or in combination with rifampicin or meropenem in a carbapenem-resistant bioluminescent Pseudomonas aeruginosa intraperitoneal murine infection model.
    Cai Y; Yang D; Wang J; Wang R
    J Antimicrob Chemother; 2018 Feb; 73(2):456-461. PubMed ID: 29149302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa.
    Aoki N; Tateda K; Kikuchi Y; Kimura S; Miyazaki C; Ishii Y; Tanabe Y; Gejyo F; Yamaguchi K
    J Antimicrob Chemother; 2009 Mar; 63(3):534-42. PubMed ID: 19147523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro Etest synergy of doripenem with amikacin, colistin, and levofloxacin against Pseudomonas aeruginosa with defined carbapenem resistance mechanisms as determined by the Etest method.
    He W; Kaniga K; Lynch AS; Flamm RK; Davies TA
    Diagn Microbiol Infect Dis; 2012 Dec; 74(4):417-9. PubMed ID: 22995366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activities of various antibiotics, alone and in combination with colistin methanesulfonate, against Pseudomonas aeruginosa strains isolated from cystic fibrosis patients.
    Güzel CB; Gerçeker AA
    Chemotherapy; 2008; 54(2):147-51. PubMed ID: 18322363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.